Decline in Case Volumes Due to COVID-19
First written in FY2020. 6 of 17 entries say "Mitigated", first in FY2021-Q2. Latest entry: FY2025-H1.
2 other companies' latest entry also says "Restated".
- FY2025-H1RestatedAnnual report
「No new business or other risks arose during the current interim consolidated accounting period. In addition, there were no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company has disclosed that there have been no material changes in the risk of a decline in case numbers due to COVID-19. - FY2024-Q3RestatedAnnual report
「During the nine-month period ended 31 December, the business environment remained generally favorable, against the backdrop of COVID-19 being reclassified as a Category V infectious disease under the Infectious Diseases Control Law in May 2023.」
Against the backdrop of COVID-19 being reclassified as a Category V infectious disease, the impact of the decline in case numbers on the business environment was reduced, and the business environment remained generally favorable. - FY2024-Q2RestatedAnnual report
「During the six-month period ended 30 September, the business environment remained generally favorable, against the backdrop of COVID-19 being reclassified as a Category V infectious disease under the Infectious Diseases Control Law in May 2023.」
Against the backdrop of COVID-19 being reclassified as a Category V infectious disease, the business environment remained generally favorable, and the reduced impact of the decline in case numbers has been reconfirmed. - FY2024-Q1MitigatedAnnual report
「During the first quarter of the current fiscal year, hospital surgery volumes increased against the backdrop of COVID-19 being reclassified as a Category V infectious disease under the Infectious Diseases Control Law in May 2023, and our sales were generally strong.」
Hospital surgery volumes increased as COVID-19 was reclassified as a Category V infectious disease, and sales remained generally strong. The impact of the decline in case volumes due to the infectious disease was mitigated from the previous fiscal year. - FY2023MitigatedAnnual report
「The number of new infections remained low from March 2023 onward. In light of the reclassification of COVID-19 under the Infectious Diseases Control Law in May 2023, among other factors, the forecast for the fiscal year ending March 2024 does not incorporate any impact from COVID-19.」
Although the spread of infections affected case volumes and performance during the current fiscal year, the forecast for the fiscal year ending March 2024 does not incorporate any impact from COVID-19. - FY2023-Q3WorsenedAnnual report
「During the third quarter of the current fiscal year, amid a wave of infections, infections with an Omicron subvariant spread rapidly from October 2022 onward. In addition to the increase in COVID-19 cases, infections among healthcare workers also became widespread, straining the healthcare delivery system and affecting case volumes related to our products.」
The spread of an Omicron subvariant from October 2022 onward and the widespread infection of healthcare workers strained the healthcare delivery system, again affecting case volumes. - FY2023-Q2Recovery after a temporary decline in case volumes due to the spread of the BA.5 variantAnnual report
「During the second quarter, infections with BA.5, a subvariant of Omicron, spread rapidly, peaking in August. In addition to the increase in infections, many healthcare workers became infected or were subject to close-contact restrictions, straining the healthcare delivery system and temporarily causing a sharp decline in case volumes related to our products. From early September onward, the infection situation stabilized and case volumes began to recover.」
Although the rapid spread of the BA.5 variant temporarily reduced case volumes in the second quarter, they began to recover from early September as the infection situation subsided. - FY2023-Q1MitigatedAnnual report
「The quasi-emergency measures to prevent the spread of disease were lifted in late March 2022, and the number of new infections trended downward during the first quarter of the current fiscal year. As a result, hospital outpatient numbers increased significantly and cases postponed during periods of infection spread were performed, leading to an increase in case volumes related to our products.」
Outpatient numbers and case volumes increased as infections declined and the measures were lifted, mitigating the impact of the COVID-19-related decline in case volumes. - FY2022RestatedAnnual report
「Sales declined as medical institutions postponed less urgent surgeries in response to the spread of COVID-19.」
Although sales continued to decline as elective cases were postponed, there were also recurring periods in which the number of surgeries recovered as infections declined and other conditions improved, and the potential for a recurrence was disclosed. - FY2022-Q3MitigatedAnnual report
「During the nine-month period of the current fiscal year, the spread of COVID-19 had a certain impact on case volumes related to our products from April through August. From September onward, however, the number of infections fell rapidly nationwide as vaccination progressed, and case volumes began to recover. As a result, sales in the third quarter increased significantly from the second quarter.」
The impact of the spread of infections on case volumes continued from April through August, but from September onward case volumes began to recover as vaccination progressed and the number of infections declined, resulting in a significant increase in third-quarter sales from the second quarter. - FY2022-Q2WorsenedAnnual report
「Meanwhile, the number of infections began to decline in September, partly as vaccination progressed nationwide. Against this backdrop, medical institutions worked to maintain normal medical services while implementing infection-prevention measures, but some facilities continued to restrict the number of surgeries and postpone elective cases.」
Although the number of infections declined in September as vaccination progressed, some facilities continued to restrict surgeries and postpone elective cases following the spread of variants from July onward and the sharp increase in infections in mid-August. - FY2022-Q1MitigatedAnnual report
「Meanwhile, case volumes overall have been recovering gradually as medical institutions implement infection-control measures and work to establish normal medical-care systems.」
Although COVID-19 continued to affect surgeries, case volumes overall showed a gradual recovery as medical institutions established infection-control measures and systems for providing routine medical care. - FY2021WorsenedAnnual report
「Meanwhile, in EP and ablation, the number of atrial fibrillation ablation procedures had been recovering from the impact of COVID-19 since June 2020, but the renewed spread of infections from January 2021 onward left full-year case volumes broadly unchanged from the previous fiscal year. Sales declined slightly, also reflecting lower reimbursement prices.」
Case volumes, which had been recovering from June 2020 onward, were constrained again by the renewed spread of infections from January 2021, resulting in a slight decline in full-year EP and ablation sales. - FY2021-Q3RestatedAnnual report
「During the nine-month period of the current fiscal year, case volumes declined sharply as medical institutions postponed elective cases with low urgency following the spread of COVID-19 in the first quarter. From June 2020 onward, however, medical institutions increasingly balanced infection-control measures with routine medical care, and case volumes gradually recovered.」
Although the decline in case volumes due to postponed elective cases continued to affect the cumulative period, case volumes continued to recover from June 2020 onward as medical institutions balanced infection-control measures with routine medical care. - FY2021-Q2MitigatedAnnual report
「Although case volumes fell substantially as medical institutions postponed elective procedures with low urgency following the spread of COVID-19, recovery became pronounced in the second-quarter consolidated accounting period as medical facilities from June 2020 onward established systems to provide necessary treatment while implementing infection-control measures.」
Although the decline in elective cases due to COVID-19 continued to affect the cumulative period, a clear recovery in case volumes emerged from June 2020 onward. - FY2021-Q1MaterialisedAnnual report
「During the first quarter of the current fiscal year, medical institutions prioritized infectious disease treatment in response to the spread of COVID-19 and postponed elective cases with low urgency. As a result, the overall number of surgeries related to our products declined year on year.」
The spread of COVID-19 led to the postponement of elective cases, and the overall number of surgeries related to our products declined year on year. EP and ablation procedures fell 12.0%, while interventional procedures declined 22.8%; case volumes began to recover from June onward. - FY2020First statedAnnual report
「As the COVID-19 pandemic prompted some medical institutions to prioritize the treatment of infectious diseases, they postponed treatment for less urgent conditions, while the number of new outpatients also declined. If this situation persists for an extended period, sales may decline.」
The postponement of elective procedures as medical institutions prioritized infectious disease treatment and the decline in new outpatient numbers had already occurred, and the risk of a prolonged decline in case volumes and sales was recorded as a key risk for the first time.